← Human Trials & Peer-Reviewed Studies
Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial
Plain-language guide to PMID 41017451 (2025): double-blind randomized controlled trial study of Tirzepatide.
Key Facts
- PMID
- 41017451
- Journal
- Diabetes, obesity & metabolism
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Hankosky ER et al. (7 authors)
- DOI
- 10.1111/dom.70143
What This Study Did, in Plain Language
What Was Tested
Researchers studied Tirzepatide in this randomized controlled trial publication.
The researchers assessed the association between tirzepatide and the 10-year predicted risk of developing cardiovascular disease (CVD) and type 2 diabetes (T2D) among three-year SURMOUNT-1 trial participants.
Who Took Part
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Tirzepatide.
The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.
This post hoc analysis applied validated risk engines that predict 10-year CVD (atherosclerotic cardiovascular disease [ASCVD], heart failure [HF], and total CVD) and T2D risk to the three-year SURMOUNT-1 clinical trial data at baseline and 176 weeks.
Changes in risk scores from baseline to week 176 were compared between tirzepatide and placebo using a mixed model of repeated measures.
What Was Measured
PubMed files the paper under topics including Diabetes Mellitus, Type 2, Prediabetic State, Obesity, Cardiovascular Diseases, Heart Disease Risk Factors, Risk Factors and Tirzepatide.
Author keywords: atherosclerosis, cardiovascular risk, incretins, obesity management and obesity management medication.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2025 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Tirzepatide compound page, all human trials.
Our Notes on the Compound
Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.